Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Craving, Binge Eating and Obesity

This study has been completed.
Information provided by (Responsible Party):
Marney A. White, Yale University Identifier:
First received: December 20, 2006
Last updated: February 12, 2014
Last verified: February 2014

This research study is designed to look at the effectiveness of bupropion for reducing binge eating in overweight persons with binge eating problems. Participants in the study will receive either bupropion or placebo ("sugar" pill, inactive medication) as an outpatient for eight weeks. In addition, participants will be given the option to receive 8 weeks of free behavioral weight loss treatment. This treatment, known to be effective for reducing binge eating and helping people lose weight, will be administered following the medication phase and at no cost.

It is expected that compared to placebo, bupropion will produce greater reductions in binge eating.

Condition Intervention Phase
Binge Eating Disorder
Drug: bupropion
Other: Placebo
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Placebo-Controlled Trial of Bupropion for the Treatment of Binge Eating Disorder

Resource links provided by NLM:

Further study details as provided by Yale University:

Primary Outcome Measures:
  • Frequency of Binge Eating Episodes [ Time Frame: One week (at post treatment) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Percent BMI Loss [ Time Frame: 8 weeks (baseline and 8 weeks) ] [ Designated as safety issue: No ]
    Percent loss in Body Mass Index

Enrollment: 61
Study Start Date: December 2005
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: bupropion
300 mg per day for 8 weeks
Other Names:
  • wellbutrin
  • zyban
Placebo Comparator: 2
Other: Placebo

Detailed Description:

The proposed study is an 8-week randomized placebo-controlled trial to test the efficacy of bupropion in treating overweight women with binge eating disorder (BED). Bupropion is an antidepressant that has demonstrated efficacy in smoking cessation and some efficacy in obesity treatment. Since cravings and depressed mood are hypothesized to contribute to binge eating episodes, bupropion is a promising psychopharmacological agent in treating binge eating and reducing weight. It is hypothesized that compared to placebo, bupropion will produce significantly greater reductions in the frequency of binge eating. Secondary goals are to explore interrelationships between treatment and changes in cravings, frequency of binge episodes, emotional eating, and weight loss. Following the medication phase of the trial, all patients will be offered 8 weeks of behavioral weight loss treatment administered by doctoral-level psychologists specializing in eating disorders and weight management.


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • BMI 25-50
  • Able to travel to clinical site (New Haven, CT) for bi-weekly visits.

Exclusion Criteria:

  • Predisposition to seizures
  • History of anorexia or bulimia nervosa
  • Current Type I or Type II diabetes mellitus
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00414167

United States, Connecticut
Yale University School of Medicine
New Haven, Connecticut, United States, 06520
Sponsors and Collaborators
Yale University
Principal Investigator: Marney A. White, PhD Yale University
  More Information

No publications provided by Yale University

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Marney A. White, Associate Professor of Psychiatry, Yale University Identifier: NCT00414167     History of Changes
Other Study ID Numbers: K23 DK71646
Study First Received: December 20, 2006
Results First Received: October 22, 2012
Last Updated: February 12, 2014
Health Authority: United States: Federal Government

Keywords provided by Yale University:
Binge eating
Emotional eating

Additional relevant MeSH terms:
Binge-Eating Disorder
Eating Disorders
Body Weight
Mental Disorders
Nutrition Disorders
Pathologic Processes
Signs and Symptoms
Signs and Symptoms, Digestive
Antidepressive Agents
Antidepressive Agents, Second-Generation
Central Nervous System Agents
Dopamine Agents
Dopamine Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses processed this record on November 25, 2014